NHS

Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London

Thursday, September 23, 2021 - 12:30pm

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.
  • The results which were published in February 2021, indicated that MDMA has the potential to be more effective at treating AUD.
  • This data will assist Awakn's progress by enabling a better design and more efficient execution of its clinical program.
  • Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.

The Scottish National Blood Transfusion Service (SNBTS) to Deploy Biolog-id Smart Storage RFID Kits Nationwide

Wednesday, September 22, 2021 - 2:50pm

The Scottish National Blood Transfusion Service (SNBTS) the specialist provider of transfusion medicine in Scotland will implement the biolog-id blood inventory devices to optimize the management of its blood products across the country.

Key Points: 
  • The Scottish National Blood Transfusion Service (SNBTS) the specialist provider of transfusion medicine in Scotland will implement the biolog-id blood inventory devices to optimize the management of its blood products across the country.
  • Designed for healthcare professionals specialized in the transfusion field, the Biolog Transfusion Solution combines RFID enabled devices powered by a proprietary IT engine and electronic labels.
  • The corner-stone devices of this solution are the RFID Smart Storage kits (SST-R) retrofitting the existing blood bank cabinets, enabling transfusion personnel to manage more precisely red blood cells units locally and at distance, and particularly to provide accurately the positioning of the blood bags within the cabinets.
  • SNBTS key priority is to ensure that NHS Scotland has enough blood to meet the transfusion needs of patients in Scotland.

CorEvitas and Inovalon Leverage Advanced Analytics to Deliver A Holistic View of the Patient

Tuesday, September 21, 2021 - 3:00pm

"We are excited to collaborate with CorEvitas to accelerate these insights with an initial focus on rheumatoid arthritis and psoriasis."

Key Points: 
  • "We are excited to collaborate with CorEvitas to accelerate these insights with an initial focus on rheumatoid arthritis and psoriasis."
  • Insights made possible through these analytics can advance clinical development, inform trial design and recruitment, substantiate value narratives, and inform patient-specific intervention plans.
  • Raymond Hill, Chairman and Chief Executive Officer for CorEvitas, noted, "As an organization, we recognize the immeasurable value of understanding the whole patient.
  • By furthering our collaboration with Inovalon, we can leverage the data-driven insights that provide integrated and actionable insights for the patient.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Monday, September 20, 2021 - 5:53pm

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Monday, September 20, 2021 - 5:51pm

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

SpectrumX’s SPC-069 Respiratory Treatment Shows Unprecedented Efficacy against Multiple Coronavirus Variants

Monday, September 20, 2021 - 9:00am

SpectrumX, a UK-based healthcare and pharmaceutical company, announced today its SPC-069 respiratory treatment has shown 100% efficacy in neutralising the most common variants of SARS-CoV-2 (Coronavirus) in an independent in vitro study.

Key Points: 
  • SpectrumX, a UK-based healthcare and pharmaceutical company, announced today its SPC-069 respiratory treatment has shown 100% efficacy in neutralising the most common variants of SARS-CoV-2 (Coronavirus) in an independent in vitro study.
  • SPC-069 is a patent-protectable nebulizer treatment which deploys HOCL (hypochlorous acid), the human bodys defence against pathogens.
  • Damien Hancox, CEO & Co-Founder of SpectrumX, said: This study shows the most promising results thus far in our battle against COVID-19 and other respiratory illnesses.
  • Our aim is the delivery of the safest and most effective treatment for all variants of COVID-19, which can dramatically reduce hospitalisation and death amongst patients.

Spex Capital and MedCity joint investment call goes live to source and fund breakthrough health-tech ventures

Monday, September 20, 2021 - 8:00am

LONDON, Sept. 20, 2021 /PRNewswire/ -- Investment firm Spex Capital and London's life sciences cluster organisation MedCity have opened their first joint call as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators. Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally. Interested companies can complete their applications for seed or series A rounds by October 27th, 2021.

Key Points: 
  • LONDON, Sept. 20, 2021 /PRNewswire/ -- Investment firm Spex Capital and London's life sciences cluster organisation MedCity have opened their first joint call as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators.
  • Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally.
  • MedCity will use its extensive networks and expertise to attract and assess applications from companies developing breakthrough digital health tech and medtech.
  • Founded in 2021 by serial health tech entrepreneur Claudio D'Angelo, London-based Spex Capital has a portfolio of six high-growth heath-tech companies.

Global Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Friday, September 17, 2021 - 2:06pm

The "Global Dry Eye Treatment Devices Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Treatment Devices Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global dry eye treatment devices market size is estimated to reach USD 414.2 million by 2028.
  • The increasing number of clinical and research activities conducted to evaluate the safety and efficacy of advanced dry eye treatment devices such as IPL and BBL will boost market growth.
  • Besides, clinical studies of these technologies are showing promising results in comparison with conventional treatment methods in dry eye treatment.

Really Simple Systems Releases New Integration with Microsoft 365

Friday, September 17, 2021 - 2:00pm

PETERSFIELD, England, Sept. 17, 2021 /PRNewswire/ -- Leading cloud software developer and vendor, Really Simple Systems , has launched of a new integration between its popular CRM and Microsoft 365, enhancing its platform integration with Microsoft Outlook, Microsoft Calendars, Contacts and Single Sign-On tools.

Key Points: 
  • PETERSFIELD, England, Sept. 17, 2021 /PRNewswire/ -- Leading cloud software developer and vendor, Really Simple Systems , has launched of a new integration between its popular CRM and Microsoft 365, enhancing its platform integration with Microsoft Outlook, Microsoft Calendars, Contacts and Single Sign-On tools.
  • Using the Microsoft 365 integration, Really Simple Systems' customers can easily synchronize their contact and calendar entries from within the CRM, without duplication across platforms.
  • John Paterson, founder and CEO at Really Simple Systems, commented: "The Really Simple Systems CRM integration with Microsoft 365 is our latest move to support small and mid-sized businesses, providing a streamlined user experience that supports their growth and relationship management.
  • The Really Simple Systems CRM Microsoft 365 integration compliments the company's existing email integration, MailSync, and Single Sign-On integration through Microsoft Azure.

UK Income Protection Insurance Market Report 2021: Cancer, Musculoskeletal Conditions and Mental Illness Accounted for 63.6% of IP Claim Costs in 2020 - ResearchAndMarkets.com

Friday, September 17, 2021 - 1:49pm

The report provides an in-depth assessment of the income protection insurance market, looking at current and historical market sizes with regards to changes in contracts and premiums.

Key Points: 
  • The report provides an in-depth assessment of the income protection insurance market, looking at current and historical market sizes with regards to changes in contracts and premiums.
  • It examines how income protection products are distributed and highlights key changes in the competitive landscape, as well as the propositions of the key market players.
  • The income protection market contracted in 2020 - new business premiums decreased by 10.1% and the number of contracts fell by 1.7%.
  • Cancer, musculoskeletal conditions, and mental illness accounted for 63.6% of IP claim costs in 2020.